"MIA PaCa-2人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

當(dāng)T25瓶復(fù)蘇細(xì)胞收到貨時(shí)，請(qǐng)觀察好細(xì)胞狀態(tài)后，將T25細(xì)胞瓶壁進(jìn)行75%酒精消毒，將T25瓶置于37度培養(yǎng)箱放置2-4h，以便穩(wěn)定細(xì)胞狀態(tài)，當(dāng)細(xì)胞密度達(dá)80%-90%，即可進(jìn)行首次傳代培養(yǎng)；干冰運(yùn)輸?shù)募?xì)胞凍存管收到貨后，需立即轉(zhuǎn)入液氮保存或直接進(jìn)行復(fù)蘇(第三天換液并檢查復(fù)蘇細(xì)胞密度，以便進(jìn)行下一步)。 能夠在實(shí)驗(yàn)室條件下進(jìn)行大量培養(yǎng)和繁殖。這種細(xì)胞系在分子生物學(xué)和生物技術(shù)研究中十分常用。

換液周期：每周2-3次

TCCPAN2 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HLEC細(xì)胞、QGP-1細(xì)胞、OP9細(xì)胞

SU-DHL1 Cells;背景說(shuō)明：間變性大細(xì)胞淋巴瘤；胸腔積液轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Hs695細(xì)胞、HEC1B細(xì)胞、Mono-Mac-6細(xì)胞

A101D Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SNU-C2B細(xì)胞、NCI-A549細(xì)胞、B6Tert-1細(xì)胞

MIA PaCa-2人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：詳見(jiàn)相關(guān)文獻(xiàn)介紹

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

公司細(xì)胞系主要引進(jìn)ATCC、DSMZ、JCRB、KCLB、RIKEN、ECACC等細(xì)胞庫(kù)，細(xì)胞系體外培養(yǎng)，它們會(huì)成長(zhǎng)為單層細(xì)胞，附著或緊貼在培養(yǎng)瓶上，或懸浮在體外的溶液中，細(xì)胞系復(fù)蘇周期短，公司細(xì)胞系狀態(tài)良好，飽滿，有光澤等優(yōu)點(diǎn)。EDTA的作用：許多人不用胰酶，只用EDTA，或者用胰酶/EDTA聯(lián)合作用。這里要明白，胰酶切割細(xì)胞外基質(zhì)的一些負(fù)責(zé)粘連和附著的蛋白，而EDTA通過(guò)螯合Ca離子，作用于整聯(lián)蛋白的活性，所以EDTA的作用更加溫和。有的人在胰酶里添加一些EDTA，或者對(duì)付特別難消化的細(xì)胞，添加多一些EDTA，就是這個(gè)道理。一般不要試圖延長(zhǎng)消化時(shí)間(如果10min還消化不下來(lái)的話)，而應(yīng)該想其它辦法。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來(lái)源說(shuō)明：細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

MIA PaCa-2人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來(lái)源：人源、鼠源等其它物種來(lái)源

C6661 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：MOLP-8細(xì)胞、THLE-3細(xì)胞、NS1細(xì)胞

SK-RC 52 Cells;背景說(shuō)明：腎癌；縱隔膜轉(zhuǎn)移;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BLO11細(xì)胞、McCoy細(xì)胞、Vertebral Cancer of the Prostate細(xì)胞

Jurkat (clone E6-1) Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SW756細(xì)胞、CEM-CCRF (CAMR)細(xì)胞、MOLT-16細(xì)胞

K7M2 wt Cells;背景說(shuō)明：骨肉瘤；肺轉(zhuǎn)移；雌性；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Caov-4細(xì)胞、J-774A.1細(xì)胞、Jeko1細(xì)胞

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞培養(yǎng)無(wú)菌操作步驟和注意事項(xiàng)：１.打開(kāi)無(wú)菌工作臺(tái)及凈化室的紫外燈，消毒半小時(shí)以上。２.進(jìn)入凈化室前先關(guān)閉紫外燈，打開(kāi)超凈臺(tái)風(fēng)機(jī)，等待３０min以上，以排盡臭氧。３.穿HAO隔離衣，戴HAO口罩，帽子。４.風(fēng)淋２分鐘。５.０.１%水泡手，擦干。６.點(diǎn)燃酒精燈;超凈臺(tái)內(nèi)應(yīng)避免放入過(guò)多的物品;使用的吸管，滴管，試管，培養(yǎng)瓶等均事先滅菌。７.打開(kāi)各類瓶蓋前先過(guò)火，以固定灰塵;打開(kāi)的瓶口、試管口過(guò)火焰，鑷子使用前應(yīng)經(jīng)火焰燒灼。８.水平式風(fēng)機(jī)的超凈臺(tái)，應(yīng)使瓶口斜置，應(yīng)盡量避免瓶口敞開(kāi)直立。９.同一根吸管或滴管不應(yīng)連續(xù)用于幾個(gè)不同的細(xì)胞系；吸取培養(yǎng)基的吸管應(yīng)離開(kāi)培養(yǎng)瓶或試管口０.５cm，避免伸入培養(yǎng)瓶口或試管口；以防止細(xì)胞系的互相混雜污染。１０.漏在培養(yǎng)瓶上或臺(tái)上的體，立即用酒精棉球擦凈。１１.操作完畢后恢復(fù)工作臺(tái)面。

RGC5 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HeLa.S3細(xì)胞、L- cell細(xì)胞、SW839細(xì)胞

ID8 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：IPI-2I細(xì)胞、RA 1細(xì)胞、FHs 74 Int細(xì)胞

624 MEL Cells;背景說(shuō)明：黑色素瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SNUC1細(xì)胞、CCD-841CoN細(xì)胞、COLO-684細(xì)胞

NCIH548 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：COLO 679細(xì)胞、HGC27細(xì)胞、NCI-H838細(xì)胞

Plaepi 34 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MDA PCa 2b細(xì)胞、NBL_S細(xì)胞、CA922細(xì)胞

H2141 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：Reuber H-35細(xì)胞、LP-1細(xì)胞、NCI-Hut 125細(xì)胞

Panc 3.27 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：J774細(xì)胞、P3JHR-1細(xì)胞、HS852.T細(xì)胞

GM03573A Cells;背景說(shuō)明：這是P３X６３Ag８(ATCCTIB-９)的一個(gè)不分泌克隆。Kappa鏈合成了但不分泌。能抗０.１mM８-氮雜鳥(niǎo)嘌呤但不能在HAT培養(yǎng)基中生長(zhǎng)。據(jù)報(bào)道它是由于缺失了３-酮類固醇還原酶活性的膽固醇營(yíng)養(yǎng)缺陷型。檢測(cè)表明肢骨發(fā)育畸形病毒(鼠痘)陰性。;傳代方法：１：２傳代，３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：Panc 5.04細(xì)胞、NOMO1細(xì)胞、LLC-PK1細(xì)胞

LO2 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：IOSE 29細(xì)胞、NR 8383細(xì)胞、Hs 695T細(xì)胞

143B Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：５傳代；每周換液２-３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：混合型;相關(guān)產(chǎn)品有：JVM2細(xì)胞、Hs-695-T細(xì)胞、V 79-4細(xì)胞

RPMI 7951 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：X63.Ag8.653細(xì)胞、BEAS 2B細(xì)胞、SU-DHL-4細(xì)胞

Y1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CaSki細(xì)胞、28SC細(xì)胞、LS-123細(xì)胞

HPBALL Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HBL100細(xì)胞、FDCP1細(xì)胞、3T3-F442A細(xì)胞

Be-Wo Cells;背景說(shuō)明：取自人絨癌腦轉(zhuǎn)移組織，在倉(cāng)鼠頰囊移植傳代８年。利用移植瘤組織進(jìn)行體外培養(yǎng)，建立細(xì)胞系。利用不同傳代方法建立了不同亞系，JEG-３是其衍生克隆。該細(xì)胞可以產(chǎn)生雌激素、孕激素、雌酮、雌二醇、雌三醇、hCG、胎盤(pán)催乳素、角蛋白。;傳代方法：１：３傳代，３-４天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：BC-022細(xì)胞、SIRC細(xì)胞、3T3(A31)細(xì)胞

PF-382 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：HuT-102細(xì)胞、Hs888 Lu細(xì)胞、SNU-398細(xì)胞

Medical University of Graz-Chordoma 1 Cells;背景說(shuō)明：骶骨脊索瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HEH2細(xì)胞、CA46細(xì)胞、B95-8細(xì)胞

Centre Antoine Lacassagne-51 Cells;背景說(shuō)明：乳腺癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LWnt-3A細(xì)胞、HT 1197.T細(xì)胞、SRA01/04細(xì)胞

Abcam HEK293T RRAGA KO Cells(提供STR鑒定圖譜)

AG12502 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRB168 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XE404 Cells(提供STR鑒定圖譜)

BY00332 Cells(提供STR鑒定圖譜)

CS97iHD180-n1 Cells(提供STR鑒定圖譜)

DA04456 Cells(提供STR鑒定圖譜)

DD3420 Cells(提供STR鑒定圖譜)

GM02408 Cells(提供STR鑒定圖譜)

hEM15A Cells;背景說(shuō)明：子宮內(nèi)膜間質(zhì)細(xì)胞；永生化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-H2591細(xì)胞、U-251_MG細(xì)胞、M-14細(xì)胞

MIA PaCa-2人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

LX-2 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代，２-３天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MDA-MB-435S細(xì)胞、OVCA433_Bast細(xì)胞、GM04678細(xì)胞

HL7702 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HPAFII細(xì)胞、MCAEC細(xì)胞、H-1373細(xì)胞

FAT Cells;背景說(shuō)明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Dunn LM8細(xì)胞、IPLB-SF 21AE細(xì)胞、H1650_CO細(xì)胞

8305C Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：６傳代;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MKN28細(xì)胞、NCI-H719細(xì)胞、SK-MEL2細(xì)胞

SKML-28 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８?jìng)鞔?，?３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：星形的;相關(guān)產(chǎn)品有：CT26.CL25細(xì)胞、TE32細(xì)胞、PG13細(xì)胞

4C11 [Mouse hybridoma against human FcRn] Cells(提供STR鑒定圖譜)

OVMANA Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：５ x １０^４ cells/ml;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SK-MEL-5細(xì)胞、LIXC-002細(xì)胞、PA317細(xì)胞

KP-N-NS Cells;背景說(shuō)明：源自腦轉(zhuǎn)移灶的腎上腺神經(jīng)母細(xì)胞瘤。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CV 1細(xì)胞、NTERA-2cl.D1細(xì)胞、OVCAR420細(xì)胞

MonoMac6 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：DMS53細(xì)胞、SUM190細(xì)胞、NCI-H810細(xì)胞

ATDC-5 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長(zhǎng)滿;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：KMST-6細(xì)胞、OVCAR-3細(xì)胞、MBMEC細(xì)胞

IMR-90 Cells;背景說(shuō)明：W.W. Nichols及其同事從一位１６周女?huà)氲姆沃腥〔?，建立了人二倍體成纖維細(xì)胞株IMR-９０。分裂潛能，病毒感受性和其它性質(zhì)都得到了充分研究，因而這株細(xì)胞可以作為WI-３８或其它標(biāo)準(zhǔn)人肺細(xì)胞株的替代株。有報(bào)道稱這株細(xì)胞在表現(xiàn)出衰老前可倍增５８次。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LC1細(xì)胞、WILL2細(xì)胞、MIN6細(xì)胞

CP-70 Cells;背景說(shuō)明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MHCC97-H細(xì)胞、SNU-5細(xì)胞、UMC-11細(xì)胞

MRMT-1 Cells;背景說(shuō)明：乳腺癌；SD;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HOEC細(xì)胞、SNU-638細(xì)胞、CORL88細(xì)胞

Saos2 Cells;背景說(shuō)明：該細(xì)胞是FoghJ和TrempeG分離和鑒定的眾多人類腫瘤細(xì)胞系中的一種；該細(xì)胞來(lái)自一位１１歲的白人女性的骨肉瘤組織?；颊呓?jīng)過(guò)放療以及甲喋呤、阿霉素、長(zhǎng)春新堿、環(huán)磷酰胺和aramycin-C等多種藥物治療。該細(xì)胞在免疫抑制小鼠中不致瘤，細(xì)胞表達(dá)表皮生長(zhǎng)因子EGF受體、轉(zhuǎn)化生長(zhǎng)因子β（１型和２型）受體。;傳代方法：１：２-１：４傳代；每周１-２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：BHK21細(xì)胞、CL MC/9細(xì)胞、RH-30細(xì)胞

GM22565 Cells(提供STR鑒定圖譜)

HAP1 MFSD8 (-) 2 Cells(提供STR鑒定圖譜)

HT(H9) Cells;背景說(shuō)明：H９細(xì)胞是HUT７８（ATCCTIB１６１）的克隆系（Callo，RC，etal）。細(xì)胞表面帶有CD３、CD４標(biāo)記。研究表明，該細(xì)胞系對(duì)人體免疫缺陷病毒（HIV-１）敏感，可用于檢測(cè)、分離和增殖HIV-１，也可用于其它人類Tcell病毒的研究。;傳代方法：１：３傳代,２-３天傳一代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：Jurkat E6-1細(xì)胞、PLA-801C細(xì)胞、CG-4細(xì)胞

CCD 1112SK Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：OVCAR-432細(xì)胞、OV1-P細(xì)胞、H-1650細(xì)胞

H2073 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代 ;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：253J B-V細(xì)胞、CSQT-2細(xì)胞、McA-RH8994細(xì)胞

SUPT-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：２-３天換液１次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣　;相關(guān)產(chǎn)品有：RIN14B細(xì)胞、Hs852T細(xì)胞、Cates 1B細(xì)胞

UCD-MLA-144 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SW-900細(xì)胞、L132細(xì)胞、SK MEL 5細(xì)胞

SK-ES1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：５傳代；每周換液２-３次;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HS-5細(xì)胞、PSN1細(xì)胞、PFSK1細(xì)胞

MARC 145 Cells;背景說(shuō)明：胚腎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CoCL2細(xì)胞、CP70細(xì)胞、T-T細(xì)胞

HCE-T Cells;背景說(shuō)明：角膜上皮細(xì)胞；Ad-SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Panc-8_13細(xì)胞、CBRH-7919細(xì)胞、HTh-74細(xì)胞

HPSI1116i-aimh_5 Cells(提供STR鑒定圖譜)

KCB 88002 Cells(提供STR鑒定圖譜)

MG1.19 Cells(提供STR鑒定圖譜)

NIMHi009-A Cells(提供STR鑒定圖譜)

RAW 264.7 Rab29 KO Cells(提供STR鑒定圖譜)

Ubigene HEK293 WDR24 KO Cells(提供STR鑒定圖譜)

WMUi023-A Cells(提供STR鑒定圖譜)

HeLa S3 ATF4 KO Cells(提供STR鑒定圖譜)

H322 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：P3-x63-Ag8 653細(xì)胞、Jiyoye細(xì)胞、293F細(xì)胞

WERI-Rb 1 Cells;背景說(shuō)明：WERI-Rb-I細(xì)胞株是１９７４年R.M. McFall 和 T.W. Sery建立的兩株人眼癌細(xì)胞系中的一株。 細(xì)胞能在Difco Bacto-Agar中存活但不形成克隆。 掃描電鏡顯示在表面囊泡，板狀偽足和微絨毛在數(shù)量上和頻率上的改變。 細(xì)胞分化研究，腫瘤治療的動(dòng)物模型和生化評(píng)價(jià)都涉及這株細(xì)胞。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：圓形細(xì)胞聚集成葡萄狀;相關(guān)產(chǎn)品有：C4-2細(xì)胞、RK13細(xì)胞、Y3-Ag1,2,3細(xì)胞

CD18 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LUDLU 1細(xì)胞、MARC-145細(xì)胞、HCC0827細(xì)胞

NCI-H165 Cells;背景說(shuō)明：非小細(xì)胞肺癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H69C細(xì)胞、MC-4細(xì)胞、HPF細(xì)胞

NCI-H716 Cells;背景說(shuō)明：從一位經(jīng)５-尿嘧啶治療的患者腹水中得到的細(xì)胞建立了這個(gè)細(xì)胞株。 與其它結(jié)直腸癌細(xì)胞系不同，這株細(xì)胞有多巴脫羧酶，細(xì)胞質(zhì)中有核心致密的內(nèi)分泌型顆粒。 這株細(xì)胞不表達(dá)TAG-７２ 或CA１９-９抗原，也不生成癌胚抗原（CEA）;傳代方法：１：３—１：６傳代，每周換液２—３次;生長(zhǎng)特性：懸浮生長(zhǎng)，聚團(tuán)，少數(shù)貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：GM 637細(xì)胞、NT2-D1細(xì)胞、PK13細(xì)胞

NCI-H716 Cells;背景說(shuō)明：從一位經(jīng)５-尿嘧啶治療的患者腹水中得到的細(xì)胞建立了這個(gè)細(xì)胞株。 與其它結(jié)直腸癌細(xì)胞系不同，這株細(xì)胞有多巴脫羧酶，細(xì)胞質(zhì)中有核心致密的內(nèi)分泌型顆粒。 這株細(xì)胞不表達(dá)TAG-７２ 或CA１９-９抗原，也不生成癌胚抗原（CEA）;傳代方法：１：３—１：６傳代，每周換液２—３次;生長(zhǎng)特性：懸浮生長(zhǎng)，聚團(tuán)，少數(shù)貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：GM 637細(xì)胞、NT2-D1細(xì)胞、PK13細(xì)胞

NW-MEL-38 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LL/2(LLc1)細(xì)胞、D324 Med細(xì)胞、NCIH1944細(xì)胞

NCI H69 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：４傳代，每周換液２次;生長(zhǎng)特性：懸浮生長(zhǎng)，聚團(tuán);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：SU.86.86細(xì)胞、CAL51細(xì)胞、SNU-387細(xì)胞

H-1755 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCIH2342細(xì)胞、COLO-680N細(xì)胞、OCI-AML-3細(xì)胞

ATN1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NOR 10細(xì)胞、GM-215細(xì)胞、H-727細(xì)胞

NCIH820 Cells;背景說(shuō)明：乳頭狀肺腺癌；淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HBE細(xì)胞、SNU-668細(xì)胞、SKBr3細(xì)胞

NCIH929 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：保持細(xì)胞密度在５×１０５—１×１０６ cells/ml之間，每周換液２—３次;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：U-251MG細(xì)胞、HuCCT-1細(xì)胞、MARC145細(xì)胞

MC3T3 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：P3-NS1/1-Ag4-1細(xì)胞、Panc 02細(xì)胞、COLO 201細(xì)胞

MeWo Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代，２-３天換液１次。;生長(zhǎng)特性：混合生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：OCI-Ly3細(xì)胞、HBVSMC細(xì)胞、OPM-2細(xì)胞

SCC-9 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Ls-174-T細(xì)胞、TU 686細(xì)胞、A2780/CP70細(xì)胞

STAN116i-148C4 Cells(提供STR鑒定圖譜)

HLE Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：PLC細(xì)胞、D10G41細(xì)胞、NB4細(xì)胞

WM115mel Cells;背景說(shuō)明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Panc203細(xì)胞、HTori-3.1細(xì)胞、UCLA RO-81A-1細(xì)胞

BBE Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：６—１：１０傳代，每周換液２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Kupffer細(xì)胞、Y1細(xì)胞、HuCCT-1細(xì)胞

CCC-HEH-2 Cells;背景說(shuō)明：心肌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SK-GT-4細(xì)胞、Tn5 B1-4細(xì)胞、MESSADX5細(xì)胞

QSG-7701 Cells;背景說(shuō)明：該細(xì)胞系來(lái)自３５歲女性的肝癌癌旁組織。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長(zhǎng)滿;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SW 626細(xì)胞、Y3-Ag1.2.3細(xì)胞、RPTC細(xì)胞

C666-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：AM細(xì)胞、WI-38細(xì)胞、AU-Mel細(xì)胞

MIA PaCa-2人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

L-540 Cells;背景說(shuō)明：霍奇金淋巴瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：FRO 81-2細(xì)胞、NCI-H2405細(xì)胞、RL-95-2細(xì)胞

MDA-MB-231-GFP Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：EJ細(xì)胞、LuCL4細(xì)胞、BTI-Tn-5B1-4細(xì)胞

SLMT1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：L 428細(xì)胞、SK-N-F1細(xì)胞、HEC-1-B細(xì)胞

WB F344 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：T-HSC細(xì)胞、HOP62細(xì)胞、P3-X63-Ag8.653細(xì)胞

NHEK Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MDA 435細(xì)胞、KP-2細(xì)胞、H-1048細(xì)胞

EA hy 926 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：GM00637B細(xì)胞、NCIH1155細(xì)胞、Sp 2817細(xì)胞

NCIH28 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，每周換液２-３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Human Pancreatic Duct Epithelial細(xì)胞、NTera 2/cl.D1細(xì)胞、MX1細(xì)胞

HS-695T Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：VP 267細(xì)胞、KRC-Y細(xì)胞、FRTL-5細(xì)胞

BayGenomics ES cell line RRF397 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XG611 Cells(提供STR鑒定圖譜)

EJ-6-2-Bam-6a Cells(提供STR鑒定圖譜)

mSG-PAC1 Cells(提供STR鑒定圖譜)

TRP 7.4 Cells(提供STR鑒定圖譜)

Ma-31 Cells(提供STR鑒定圖譜)

" "PubMed=7809022; DOI=10.1097/00006676-199409000-00018

Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.

Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.

Pancreas 9:657-661(1994)

PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x; PMCID=PMC5919355

Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T., Imamura M., Hiai H., Fukumoto M.

K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.

Jpn. J. Cancer Res. 85:1005-1014(1994)

PubMed=8026879; DOI=10.1002/ijc.2910580207

Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.

Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.

Int. J. Cancer 58:185-191(1994)

PubMed=8194712; DOI=10.1016/0016-5085(94)90422-7

Simon B., Weinel R., Hohne M., Watz J., Schmidt J., Kortner G., Arnold R.

Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.

Gastroenterology 106:1645-1651(1994)

PubMed=21607521; DOI=10.3892/or.1.6.1223

Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.

Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.

Oncol. Rep. 1:1223-1227(1994)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4; PMCID=PMC1850008

Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.

Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.

Am. J. Pathol. 154:525-536(1999)

PubMed=11115575; DOI=10.3892/or.8.1.89

Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.

Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.

Oncol. Rep. 8:89-92(2001)

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U

Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.

Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.

Int. J. Cancer 91:340-344(2001)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C

Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.

Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.

Int. J. Cancer 91:350-358(2001)

PubMed=11787853; DOI=10.1007/s004280100474

Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.

Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

Virchows Arch. 439:798-802(2001)

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4

Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.

A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.

Virchows Arch. 442:444-452(2003)

PubMed=14695172

Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.

Cancer Res. 63:8614-8622(2003)

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521; PMCID=PMC4305696

Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.

Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

World J. Gastroenterol. 11:1521-1528(2005)

PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721

Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E., Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H., Kern S.E.

Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.

Cancer Res. 66:7920-7928(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001

Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.

Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.

Biologicals 35:195-202(2007)

PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x; PMCID=PMC3828895

Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.

Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.

J. Cell. Mol. Med. 12:2823-2835(2008)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x; PMCID=PMC11158928

Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.

Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.

Cancer Sci. 99:986-994(2008)

PubMed=18575732; DOI=10.3892/or.20.1.155

Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N., Yoshino S., Hazama S.

Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.

Oncol. Rep. 20:155-163(2008)

CLPUB00416

Oberlin L.

Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.

Thesis VMD (2009); Justus-Liebig-Universitat Giessen; Giessen; Germany

PubMed=19077451; DOI=10.1159/000178871

Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.

Genome-wide analysis of pancreatic cancer using microarray-based techniques.

Pancreatology 9:13-24(2009)

PubMed=19188929; DOI=10.1038/tpj.2008.20

Guo J., Anderson M.G., Tapang P., Palma J.P., Rodriguez L.E., Niquette A.L., Li J.-L., Bouska J.J., Wang G., Semizarov D., Albert D.H., Donawho C.K., Glaser K.B., Shah O.J.

Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.

Pharmacogenomics J. 9:90-102(2009)

PubMed=20037478; DOI=10.4161/cbt.8.21.9685; PMCID=PMC2824894

Kent O.A., Mullendore M.E., Wentzel E.A., Lopez-Romero P., Tan A.-C., Alvarez H., West K.M., Ochs M.F., Hidalgo M., Arking D.E., Maitra A., Mendell J.T.

A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.

Cancer Biol. Ther. 8:2013-2024(2009)

PubMed=19904223; DOI=10.1097/MPA.0b013e3181bc44dd; PMCID=PMC2835986

Xiao J., Lee W.-N.P., Zhao Y.-C., Cao R., Go V.L.-W., Recker R.R., Wang Q., Xiao G.G.-S.

Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media.

Pancreas 39:e17-e23(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963; PMCID=PMC2860631

Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J.G., Scaife C.L., Firpo M.A., Mulvihill S.J.

Phenotype and genotype of pancreatic cancer cell lines.

Pancreas 39:425-435(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396

Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Cancer Discov. 2:172-189(2012)

DOI=10.4172/2324-9293.1000104

Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R., Saeger H.-D.

Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.

Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013)

PubMed=23386380; DOI=10.1002/jcb.24506

Bose B., Shenoy P.S.

Non insulin producing cell line, MIA PaCa-2 is rendered insulin producing in vitro via mesenchymal epithelial transition.

J. Cell. Biochem. 114:1642-1652(2013)

PubMed=25167228; DOI=10.1038/bjc.2014.475; PMCID=PMC4453732

Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Br. J. Cancer 111:1788-1801(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25485960; DOI=10.4161/15384047.2014.986967; PMCID=PMC4623403

Samulitis B.K., Pond K.W., Pond E., Cress A.E., Patel H., Wisner L., Patel C., Dorr R.T., Landowski T.H.

Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.

Cancer Biol. Ther. 16:43-51(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112; PMCID=PMC4538616

Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

PubMed=26884312; DOI=10.1038/srep21648; PMCID=PMC4756684

Gradiz R., Silva H.C., Carvalho L., Botelho M.F., Mota-Pinto A.

MIA PaCa-2 and PANC-1 -- pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors.

Sci. Rep. 6:21648-21648(2016)

PubMed=27067801; DOI=10.1186/s12885-016-2297-y; PMCID=PMC4828819

Miura K., Kimura K., Amano R., Yamazoe S., Ohira G., Murata A., Nishio K., Hasegawa T., Yashiro M., Nakata B., Ohira M., Hirakawa K.

Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2.

BMC Cancer 16:268.1-268.13(2016)

PubMed=27259358; DOI=10.1074/mcp.M116.058313; PMCID=PMC4974343

Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J.-M., Daly R.J.

Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.

Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051; PMCID=PMC6343826

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)

PubMed=31037374; DOI=10.1007/s00216-019-01814-1

Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T., Wittel U.A., Kammerer B.

Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry.

Anal. Bioanal. Chem. 411:6319-6328(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402.e16(2020)"